TW200512197A - Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptors - Google Patents

Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptors

Info

Publication number
TW200512197A
TW200512197A TW093119215A TW93119215A TW200512197A TW 200512197 A TW200512197 A TW 200512197A TW 093119215 A TW093119215 A TW 093119215A TW 93119215 A TW93119215 A TW 93119215A TW 200512197 A TW200512197 A TW 200512197A
Authority
TW
Taiwan
Prior art keywords
nervous system
central nervous
subunit
selectivity
alpha
Prior art date
Application number
TW093119215A
Other languages
English (en)
Inventor
Barbara Langen
Chris Rundfeldt
Rita Dost
Hartmut Luddens
Holger Rabe
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of TW200512197A publication Critical patent/TW200512197A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
TW093119215A 2003-07-11 2004-06-29 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptors TW200512197A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48667803P 2003-07-11 2003-07-11

Publications (1)

Publication Number Publication Date
TW200512197A true TW200512197A (en) 2005-04-01

Family

ID=34062138

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093119215A TW200512197A (en) 2003-07-11 2004-06-29 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptors

Country Status (17)

Country Link
US (2) US20050032863A1 (zh)
EP (2) EP1646386A2 (zh)
JP (1) JP2009513539A (zh)
KR (1) KR20060032633A (zh)
CN (2) CN1822836A (zh)
AR (1) AR045013A1 (zh)
AU (1) AU2004255414A1 (zh)
BR (1) BRPI0412512A (zh)
CA (1) CA2531861A1 (zh)
MX (1) MXPA05013196A (zh)
NO (1) NO20060686L (zh)
NZ (1) NZ544251A (zh)
RU (1) RU2354377C2 (zh)
TW (1) TW200512197A (zh)
UA (1) UA87982C2 (zh)
WO (1) WO2005004867A2 (zh)
ZA (1) ZA200509169B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101395142B (zh) * 2006-03-08 2012-03-28 弗·哈夫曼-拉罗切有限公司 4-氨基-1,5-取代的1,5-二氢-咪唑-2-酮
WO2011029104A1 (en) 2009-09-04 2011-03-10 Vanderbilt University Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
KR20140057604A (ko) 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
CN104199105A (zh) * 2014-08-27 2014-12-10 中国石油天然气集团公司 高密度三维勘探中初至的拾取方法及拾取装置
CN109564229A (zh) * 2016-07-11 2019-04-02 兰维尔健康有限公司 基于味觉识别的诊断相关性的方法
KR102489109B1 (ko) * 2020-06-02 2023-01-16 부산대학교 산학협력단 아세틸콜린 수용체 변이 유전자를 유효성분으로 포함하는 근긴장 이상증 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90869C (fi) * 1986-11-14 1994-04-11 Tanabe Seiyaku Co Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
AU5884696A (en) 1995-06-23 1997-01-22 Bausch & Lomb Incorporated Method for cleaning contact lenses utilizing polysulfonates
DE19532668A1 (de) * 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5869481A (en) * 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
DE19721580A1 (de) * 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
WO1999037370A1 (en) 1998-01-22 1999-07-29 Precedence Publishing, Inc. Game using collectibles as playing pieces
GB9821179D0 (en) 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
GB9929687D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
GB0122696D0 (en) * 2001-09-20 2001-11-14 Merck Sharp & Dohme Therapeutic agents
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs

Also Published As

Publication number Publication date
CN101254189A (zh) 2008-09-03
US20080114032A1 (en) 2008-05-15
US20050032863A1 (en) 2005-02-10
AR045013A1 (es) 2005-10-12
RU2354377C2 (ru) 2009-05-10
EP2027856A1 (en) 2009-02-25
WO2005004867A2 (en) 2005-01-20
MXPA05013196A (es) 2006-03-09
WO2005004867A3 (en) 2005-04-21
CA2531861A1 (en) 2005-01-20
NO20060686L (no) 2006-03-14
UA87982C2 (ru) 2009-09-10
AU2004255414A1 (en) 2005-01-20
JP2009513539A (ja) 2009-04-02
NZ544251A (en) 2009-12-24
RU2006104118A (ru) 2006-06-10
EP1646386A2 (en) 2006-04-19
KR20060032633A (ko) 2006-04-17
ZA200509169B (en) 2006-07-26
CN1822836A (zh) 2006-08-23
BRPI0412512A (pt) 2006-09-19

Similar Documents

Publication Publication Date Title
LUC00217I2 (zh)
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
RS20060129A (en) /1,8/naphthyridin-2-ones and related compounds for the treatment of schizophrenia
HK1101178A1 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
DE60222698D1 (de) Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
BR0200283A (pt) Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
DE60227576D1 (de) 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS
WO2007023310A3 (en) Stimulation of neurogenesis with help of alk inhibitors
NO20060686L (no) Fremgangsmate for behandling eller hindring av forstyrrelser i sentralnervesystemet med forbindelser som er selektive for alfa 3 subenhet til benzodiazepinreseptor
NO20050385L (no) Anvendelse av PP2A-fosfatasemodulatorer i behandlingen av mentale lidelser
ATE402704T1 (de) Dopamin-d3-rezeptor-liganden zur behandlung von sucht
PL1978959T3 (pl) Pochodne piperydyny i piperazyny
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
HK1130433A1 (en) Piperidine and piperazine derivatives
SV2006002304A (es) "azabenzoxazoles para el tratamiento de trastornos del snc" ref.pc32518a
DE602004013540D1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
PL381615A1 (pl) Piperazynowe pochodne alkilooksyndoli
UA85198C2 (ru) Производные морфолина как ингибиторы повторного поглощения норэпинефрина
HRP20030956A2 (en) USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
WO2004020455A3 (en) Genes involved in neuropsychiatric disorders
HRP20030959A2 (zh)
BR0314031A (pt) Tratamento de rinite não-alérgica por inibidores seletivos de fosfodiesterase 4
UA97251C2 (ru) Соединения как модуляторы опиоидного рецептора